Mediclinic International PLC
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic" or the "Company")
23 November 2017
Purchase of shares in Mediclinic by Jurgens Myburgh, Chief Financial Officer
On 21 November 2017, Jurgens Myburgh, Chief Financial Officer, acquired 30,000 shares in the Company at ZAR 100.70 per share. Accordingly, Mr Myburgh now owns a total of 60,000 shares in Mediclinic International plc.
The following notification is made in accordance with Articles 19.1 and 19.3 of the Market Abuse Regulation.
NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1. |
Details of PDMR / person closely associated with them ("PCA")
|
|||||
a) |
Name |
Petrus Jurgens Myburgh
|
||||
2. |
Reason for the notification
|
|||||
a) |
Position / status |
Chief Financial Officer of the Company
|
||||
b) |
Initial notification / amendment
|
Initial Notification
|
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|||||
a) |
Name |
Mediclinic International plc
|
||||
b) |
LEI |
2138002S5BSBIZTD5I60
|
||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|||||
a) |
Description of the financial instrument
Identification Code
|
Ordinary Shares
GB00B8HX8Z88 |
||||
b) |
Nature of the transaction
|
Purchase of shares |
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information
Aggregated volume
Price |
30,000
ZAR 100.70 per share
|
||||
e) |
Date of the transaction
|
21 November 2017; 08:00 UTC |
||||
f) |
Place of the transaction
|
Johannesburg Stock Exchange |
About Mediclinic International plc
Mediclinic is an international private healthcare group with operating platforms in Southern Africa (South Africa and Namibia), Switzerland and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a LSE listed and UK-based private healthcare group.
Mediclinic comprises 75 hospitals and 29 clinics. Mediclinic Southern Africa operates 49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 000 inpatient beds in total; Hirslanden operates 17 private acute care facilities and 4 clinics in Switzerland with more than 1 700 inpatient beds; and Mediclinic Middle East operates 6 hospitals and 23 clinics with more than 700 inpatient beds in the United Arab Emirates.
During February 2016, the combination of the Company (previously named Al Noor Hospitals Group plc), with operations mainly in Abu Dhabi in the United Arab Emirates, and Mediclinic International Limited was completed. Mediclinic International Limited was a South African based international private healthcare group founded in 1983 and listed on the JSE, the South African stock exchange, since 1986, with operations in South Africa, Namibia, Switzerland and the United Arab Emirates (mainly in Dubai). The combination resulted in the renaming of the enlarged group to Mediclinic International plc.
Mediclinic has a primary listing on the Main Market of the LSE, with secondary listings on the JSE in South Africa and the NSX in Namibia.
For further information, please contact:
Victoria Dalby / Caroline Emmet
+44 (0)20 7954 9600
James Arnold, Head of Investor Relations
+44 (0)20 3786 8181
FTI Consulting
Brett Pollard / Debbie Scott (UK)
+44 (0)20 3727 1000
Frank Ford (South Africa)
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker: Morgan Stanley & Co International plc
JSE sponsor: RAND MERCHANT BANK (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd